Real World Benefit Related to Improving Corneal Staining

EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies

EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO

Now Viewing

EP: 3.Real World Benefit Related to Improving Corneal Staining

EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023

EP: 5.Updates from the SAHARA Trial at AAO 2023

EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance

This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.

Adler discusses why the results showing improvement in both symptoms and signs with switching from Restasis (cyclosporine ophthalmic emulsion 0.05%) to Cequa (cyclosporine ophthalmic solution 0.09%) have real-world relevance.

He notes that in practice, both patients and doctors use symptoms as an overall indicator of treatment success. Symptom relief matters greatly in determining real-world effectiveness.

As for signs, improving corneal staining is important because this directly impacts blurry vision, which is a major frustration for patients. Even after otherwise successful cataract or refractive surgery, persisting corneal staining from dry eye can cause blurred vision and patient dissatisfaction.

By demonstrating the ability to improve both symptoms and vision-blurring corneal signs in incomplete Restasis responders switched to Cequa, study results offer meaningful real-world benefits.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.